tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Precancerous Conditions D011230 48 associated lipids
Fatty Liver D005234 48 associated lipids
Psoriasis D011565 47 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Burns D002056 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Cataract D002386 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Diarrhea D003967 32 associated lipids
Liver Diseases D008107 31 associated lipids
Cardiomegaly D006332 31 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Endotoxemia D019446 27 associated lipids
Brain Diseases D001927 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Hypersensitivity D006967 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Stoller G et al. An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. 1996 FEBS Lett. pmid:8612805
Márquez JA and Serrano R Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. 1996 FEBS Lett. pmid:8612770
Galat A A note on circular-dichroic-constrained prediction of protein secondary structure. 1996 Eur. J. Biochem. pmid:8612612
Brousse N and Goulet O Small bowel transplantation. 1996 BMJ pmid:8611766
Furth S et al. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. 1996 Pediatr. Nephrol. pmid:8611359
Johnson MW et al. Hepatitis C viral infection in liver transplantation. 1996 Arch Surg pmid:8611094
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Singh N et al. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. 1996 Transplantation pmid:8610349
Peters KP et al. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. 1996 J. Mol. Biol. pmid:8609611
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Busuttil RW et al. General guidelines for the use of tacrolimus in adult liver transplant patients. 1996 Transplantation pmid:8607197
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Greeno EW et al. Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. 1996 Transfusion pmid:8607158
Fay JW et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. 1996 Blood pmid:8605372
Murao K et al. Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. 1996 Endocrinology pmid:8603582
Vilquin JT et al. Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. 1996 J. Cell Biol. pmid:8601607
Lake KD and Canafax DM Important interactions of drugs with immunosuppressive agents used in transplant recipients. 1995 J. Antimicrob. Chemother. pmid:8601538
Rifai N et al. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. 1996 Clin. Biochem. pmid:8601324
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Beretta L et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. 1996 EMBO J. pmid:8599949
Ma J et al. Rectification of skeletal muscle ryanodine receptor mediated by FK506 binding protein. 1995 Biophys. J. pmid:8599646
Dan Y et al. IL-3 augments TCR-mediated responses of type 2 CD4 T cells. 1996 J. Immunol. pmid:8598473
Hammond TG and Kind CN Pancreatic and nephrotoxicity of immunomodulator compounds. 1995 Toxicol. Lett. pmid:8597171
Taylor PJ et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. 1996 Clin. Chem. pmid:8595724
Sakane T et al. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions]. 1995 Ryumachi pmid:8594659
Dhar DK et al. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. 1996 J. Surg. Res. pmid:8592405
Cardenas ME et al. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 1995 Curr. Opin. Nephrol. Hypertens. pmid:8591053
Lohse DL et al. Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. 1995 Structure pmid:8590008
Jusko WJ et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). 1995 Ther Drug Monit pmid:8588229
McMaster P et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. 1995 Ther Drug Monit pmid:8588228
Jusko WJ Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. 1995 Ther Drug Monit pmid:8588227
Fung JJ and Starzl TE FK506 in solid organ transplantation. 1995 Ther Drug Monit pmid:8588226
Thomson AW et al. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. 1995 Ther Drug Monit pmid:8588225
Soldin SJ Receptor (immunophilin-binding) assay for immunosuppressive drugs. 1995 Ther Drug Monit pmid:8588223
Goodall T et al. FK506-induced endothelin release by cultured rat mesangial cells. 1995 J. Cardiovasc. Pharmacol. pmid:8587453
Takeda Y et al. Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature. 1995 J. Cardiovasc. Pharmacol. pmid:8587392
Büttemeyer R et al. Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression. 1995 Ann Plast Surg pmid:8585683
Gonschior AK et al. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. 1995 Ther Drug Monit pmid:8585114
Hemenway CS et al. vph6 mutants of Saccharomyces cerevisiae require calcineurin for growth and are defective in vacuolar H(+)-ATPase assembly. 1995 Genetics pmid:8582630
Sekigawa I et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. 1995 J. Clin. Immunol. pmid:8576317
Wesselborg S et al. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). 1996 J. Biol. Chem. pmid:8576111
Sano T et al. FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. 1995 Eur. Respir. J. pmid:8575571
Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. 1995 Hum. Gene Ther. pmid:8573612
Castillo Lugo JA Clinical and experimental immunosuppression. 1995 May-Jun Bol Asoc Med P R pmid:8573248
Charters AR et al. Developmental expression of FK506 binding proteins and calcineurin in rat brain. 1995 Biochem. Soc. Trans. pmid:8566310
Tanida I et al. Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. 1996 FEBS Lett. pmid:8566225
Itoh S and Navia MA Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). 1995 Protein Sci. pmid:8563622
Stillman IE et al. FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model. 1995 Lab. Invest. pmid:8558840
Ryffel B et al. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. 1995 Immunopharmacology pmid:8557519
Fukunaga T et al. Osteogenesis in xenogeneic bone transplantation, using an immunosuppressant. Rabbit-rat experiments. 1995 Acta Orthop Scand pmid:8553828
Delaney CP et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. 1996 J. Clin. Invest. pmid:8550837
Koch K et al. CP-123,369: a potent, orally active immunosuppressive agent. 1995 Inflamm. Res. pmid:8548388
Gharpure VS et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:8547871
Aoyama H et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. 1995 Br. J. Dermatol. pmid:8547017
Fryer JP et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. 1996 Arch Surg pmid:8546583
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Andoh TF et al. Functional and structural characteristics of experimental FK 506 nephrotoxicity. 1995 Clin. Exp. Pharmacol. Physiol. pmid:8542679
Jonas S et al. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial. 1995 Clin Transplant pmid:8541635
Bersztel A et al. Deoxyspergualin is synergistic with cyclosporin A, but not with FK506 in a rat heart allograft transplantation model. 1995 Transplant. Proc. pmid:8540095
Felldin M et al. Rescue therapy with Tacrolimus (FK506) in renal transplant recipients--a multicenter analysis. 1995 Transplant. Proc. pmid:8540032
Tai J et al. In vivo function of pig islet xenografts in immunosuppressed diabetic mice. 1995 Transplant. Proc. pmid:8539968
Wennberg L et al. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:8539967
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Tesi RJ et al. Conversion of pancreas transplants to FK 506 from CsA. 1995 Transplant. Proc. pmid:8539828
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823
Henley SE et al. Lipids following pancreas transplantation in recipients receiving FK 506. 1995 Transplant. Proc. pmid:8539809
Hariharan S et al. Conversion from cyclosporine to tacrolimus after pancreas transplantation. 1995 Transplant. Proc. pmid:8539799
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Faerman CH and Karplus PA Consensus preferred hydration sites in six FKBP12-drug complexes. 1995 Proteins pmid:8539241
Eckert B et al. Calcium-mobilizing insulin secretagogues stimulate transcription that is directed by the cyclic adenosine 3',5'-monophosphate/calcium response element in a pancreatic islet beta-cell line. 1996 Endocrinology pmid:8536617
Ihara H et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. 1995 Int. J. Urol. pmid:8536129
Orengo CA et al. Structural similarity between the pleckstrin homology domain and verotoxin: the problem of measuring and evaluating structural similarity. 1995 Protein Sci. pmid:8535234
Ockenfels HM et al. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. 1995 Dermatology (Basel) pmid:8534940
Zhu X et al. Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells. 1995 Ann. Hematol. pmid:8534762
Kaplan A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. 1995 J. Dermatol. Sci. pmid:8534611
Mugiya S et al. Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. 1995 Thromb. Res. pmid:8533130
Büttemeyer R et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. 1996 Plast. Reconstr. Surg. pmid:8532772
Tamura K FK506: mechanism of immunosuppression and adverse-effects. 1995 J Toxicol Sci pmid:8531246
Arreaza G et al. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. 1995 J. Clin. Endocrinol. Metab. pmid:8530625
Ku YM et al. Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. 1995 Am J Health Syst Pharm pmid:8528874
Lionetti P et al. Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. 1995 Adv. Exp. Med. Biol. pmid:8525974
Kissinger CR et al. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. 1995 Nature pmid:8524402
Cameron AM et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. 1995 Cell pmid:8521476
Krentz AJ et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. 1993 Diabetes pmid:7694879
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Zuany-Amorim C et al. Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. 1993 Br. J. Pharmacol. pmid:7694762
White DJ Immunosuppression for heart transplantation. 1993 Br. J. Biomed. Sci. pmid:7694717
Bierer BE et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. 1993 Curr. Opin. Immunol. pmid:7694595
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Jusko WJ and Kobayashi M Therapeutic monitoring of tacrolimus (FK 506) 1993 Ther Drug Monit pmid:7694395
Travis J Making molecular matches in the cell. 1993 Science pmid:7694368
Spencer DM et al. Controlling signal transduction with synthetic ligands. 1993 Science pmid:7694365
Dawson TM et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7694293